GSK, Avenue Fleming, 20 1300, Wavre, Belgium.
Present address: Takeda Pharmaceutical Company Limited, Zurich, Switzerland.
BMC Public Health. 2022 May 31;22(1):1078. doi: 10.1186/s12889-022-13342-2.
Invasive meningococcal disease (IMD) is uncommon, life-threatening, with many diverse sequelae. The aims were to: 1) comprehensively characterise the sequelae; 2) have a systematic application for sequelae impact in economic evaluation (EE).
Sequelae categorised as physical/neurological or psychological/behavioural were identified from a systematic review of IMD observational studies (OS) and EEs in high-income countries (published 2001-2020). A comprehensive map and EE-relevant list, respectively, included physical/neurological sequelae reported in ≥2OS and ≥ 2OS + 2EE (≥1OS and ≥ 1OS + 1EE for psychological/behavioural). Sequelae proportions were selected from the highest quality studies reporting most sequelae. Three medical experts independently evaluated the clinical impact of findings.
Sixty-Six OS and 34 EE reported IMD sequelae. The comprehensive map included 44 sequelae (30 physical/neurological, 14 psychological/behavioural), of which 18 (14 physical/neurological and 4 psychological/behavioural) were EE-relevant. Experts validated the study and identified gaps due to limited evidence, underreporting of psychological/behavioural sequelae in survivors/their families, and occurrence of multiple sequelae in the acute phase and long-term.
The considerable burden of IMD sequelae on survivors and their families is potentially underestimated in EE, due to underreporting and poorly-defined subtle sequelae. When assessing IMD burden and potential interventions e.g., vaccination, sequelae range and duration, underreporting, and indirect burden on dependents should be considered.
侵袭性脑膜炎球菌病(IMD)罕见且危及生命,伴有多种不同的后遗症。本研究旨在:1)全面描述后遗症;2)在经济评估(EE)中系统地应用后遗症影响。
从高收入国家发表于 2001 年至 2020 年的 IMD 观察性研究(OS)和 EE 中,系统性地确定了身体/神经或心理/行为后遗症。分别包括在≥2 个 OS 和≥2OS+2EE(≥1OS 和≥1OS+1EE 为心理/行为)中报告的身体/神经后遗症的全面图谱和 EE 相关列表。从报告最多后遗症的最高质量研究中选择了后遗症的比例。三位医学专家独立评估了研究结果的临床影响。
有 66 项 OS 和 34 项 EE 报告了 IMD 后遗症。全面图谱包括 44 种后遗症(30 种身体/神经,14 种心理/行为),其中 18 种(14 种身体/神经和 4 种心理/行为)与 EE 相关。专家验证了该研究,并确定了由于证据有限、幸存者及其家属报告的心理/行为后遗症不足以及急性和长期后遗症多种后遗症的发生而导致的差距。
由于报告不足和定义不明确的细微后遗症,EE 中 IMD 后遗症对幸存者及其家属的负担可能被低估。在评估 IMD 负担和潜在干预措施时,例如疫苗接种,应考虑后遗症范围和持续时间、报告不足以及对依赖者的间接负担。